Arbutus Biopharma Corporation

2.61-0.0700-2.61%Vol 670.43K1Y Perf -20.47%
Jun 28th, 2022 16:00 DELAYED
BID2.58 ASK2.70
Open2.66 Previous Close2.68
Pre-Market- After-Market2.58
 - -  -0.03 -1.15%
Target Price
7.13 
Analyst Rating
Strong Buy 1.00
Potential %
173.18 
Finscreener Ranking
★★★★★     60.05
Insiders Trans % 3/6/12 mo.
-/-/- 
Value Ranking
★★★     52.23
Insiders Value % 3/6/12 mo.
-/-/- 
Growth Ranking
★★★★     59.58
Insiders Shares Cnt. % 3/6/12 mo.
-/-/- 
Income Ranking
 —    -
Price Range Ratio 52W %
14.88 
Earnings Rating
Strong Buy
Market Cap388.18M 
Earnings Date
4th Aug 2022
Alpha0.01 Standard Deviation0.30
Beta2.66 

Today's Price Range

2.582.71

52W Range

1.936.50

5 Year PE Ratio Range

-2.40-1.10

Summary:

Neutral

Technical Indicators: Neutral
Moving Averages: Neutral
Performance
1 Week
-1.47%
1 Month
8.06%
3 Months
-6.62%
6 Months
-29.84%
1 Year
-20.47%
3 Years
28.85%
5 Years
-25.56%
10 Years
30.73%

TickerPriceChg.Chg.%
ABUS2.61-0.0700-2.61
AAPL137.44-4.2200-2.98
GOOG2 251.43-81.0200-3.47
MSFT256.48-8.4100-3.17
XOM91.502.47002.77
WFC40.18-0.0600-0.15
JNJ176.94-5.1800-2.84
FB196.640.99000.51
GE65.88-0.8300-1.24
JPM115.82-0.5600-0.48
Financial StrengthValueIndustryS&P 500US Markets
5.10
5.30
0.01
0.02
-26.50
Leverage Ratio 2.90
ProfitabilityValueIndustryS&P 500US Markets
-22.60
-319.70
-311.80
-1 280.60
-
RevenueValueIndustryS&P 500US Markets
21.46M
0.14
34.35
30.97
Earnings HistoryEstimateReportedSurprise %
Q01 2022-0.13-0.1115.38
Q04 2021-0.16-0.156.25
Q03 2021-0.24-0.240.00
Q02 2021-0.21-0.23-9.52
Q01 2021-0.22-0.214.55
Q04 2020-0.21-0.23-9.52
Q03 2020-0.20-0.27-35.00
Q02 2020-0.23-0.25-8.70
Earnings Per EndEstimateRevision %Trend
6/2022 QR-0.137.14Positive
9/2022 QR-0.137.14Positive
12/2022 FY-0.518.93Positive
12/2023 FY-0.583.33Positive
Next Report Date4th Aug 2022
Estimated EPS Next Report-0.13
Estimates Count2
EPS Growth Next 5 Years %-
Volume Overview
Volume670.43K
Shares Outstanding148.73K
Shares Float107.10M
Trades Count4.96K
Dollar Volume1.76M
Avg. Volume1.18M
Avg. Weekly Volume1.26M
Avg. Monthly Volume1.06M
Avg. Quarterly Volume1.22M

Arbutus Biopharma Corporation (NASDAQ: ABUS) stock closed at 2.68 per share at the end of the most recent trading day (a -5.63% change compared to the prior day closing price) with a volume of 868.27K shares and market capitalization of 388.18M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 80 people. Arbutus Biopharma Corporation CEO is William H. Collier.

The one-year performance of Arbutus Biopharma Corporation stock is -20.47%, while year-to-date (YTD) performance is -31.11%. ABUS stock has a five-year performance of -25.56%. Its 52-week range is between 1.93 and 6.5, which gives ABUS stock a 52-week price range ratio of 14.88%

Arbutus Biopharma Corporation currently has a PE ratio of -3.90, a price-to-book (PB) ratio of 2.55, a price-to-sale (PS) ratio of 18.58, a price to cashflow ratio of 7 665.10, a PEG ratio of 2.32, a ROA of -45.10%, a ROC of -123.80% and a ROE of -130.57%. The company’s profit margin is -%, its EBITDA margin is -311.80%, and its revenue ttm is $21.46 Million , which makes it $0.14 revenue per share.

Of the last four earnings reports from Arbutus Biopharma Corporation, there were 2 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $-0.13 for the next earnings report. Arbutus Biopharma Corporation’s next earnings report date is 04th Aug 2022.

The consensus rating of Wall Street analysts for Arbutus Biopharma Corporation is Strong Buy (1), with a target price of $7.13, which is +173.18% compared to the current price. The earnings rating for Arbutus Biopharma Corporation stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Arbutus Biopharma Corporation has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Arbutus Biopharma Corporation has a Neutral technical analysis rating based on Technical Indicators (ADX : 13.70, ATR14 : 0.19, CCI20 : 64.33, Chaikin Money Flow : 0.14, MACD : 0.08, Money Flow Index : 64.77, ROC : 0.00, RSI : 53.43, STOCH (14,3) : 59.09, STOCH RSI : 0.04, UO : 53.31, Williams %R : -40.91), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Arbutus Biopharma Corporation in the last 12-months were:

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
4 (100.00 %)
4 (100.00 %)
4 (100.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.00
Strong Buy
1.00
Strong Buy
1.00

Arbutus Biopharma Corporation

Arbutus Biopharma Corp is a biopharmaceutical company. The company discovers, develops and commercializes cure for patients suffering from Hepatitis B infection. It is focused on developing a portfolio of drug candidates with multiple mechanisms of action and also involved in licensing of Lipid nanoparticle technology.

CEO: William H. Collier

Telephone: +1 267 469-0914

Address: 701 Veterans Circle, Warminster 18974, PA, US

Number of employees: 80

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

67%33%

Bearish Bullish

63%37%

Bearish Bullish

62%38%

TipRanks News for ABUS

News

Stocktwits